Educational reference only. Informational material drawn from peer-reviewed literature. Not medical advice and not a recommendation to use, dose, or modify any therapy. Decisions about hormone therapy should be made with a qualified healthcare provider.
Overview
Overview
Exenatide is a synthetic version of exendin-4, a 39-amino-acid peptide first identified in the venom of the Gila monster (Heloderma suspectum). It shares about 53% sequence homology with human GLP-1 and activates the GLP-1 receptor. Unlike native GLP-1, which lasts only minutes, it resists breakdown by the enzyme DPP-4.
It was the first drug of the incretin-mimetic class (approved in the US in 2005) and paved the way for liraglutide, semaglutide, and tirzepatide. Two formulations were marketed: a twice-daily immediate-release injection (Byetta) and once-weekly extended-release microspheres (Bydureon, Bydureon BCise). In type 2 diabetes it improves glucose control and causes modest weight loss. It was also studied as a potential disease-modifying therapy for Parkinson's disease; the large phase 3 trial was negative.
Market status (US): the original Bydureon kit was withdrawn in 2021. Byetta was discontinued on 25 October 2024, and Bydureon BCise on 28 October 2024. Availability outside the US varies by market. Aliases: exendin-4 (synthetic), AC2993.
Forms
Available forms & half-lives
| Form | Approximate half-life |
|---|---|
| Subcutaneous injection, immediate-release (Byetta; US product discontinued) | ~2.4 hours; measurable for about 10 hours after an injection |
| Subcutaneous injection, extended-release PLGA microspheres (Bydureon / BCise; US products discontinued) | Gradual release over weeks; plasma levels fall below the quantifiable limit about 10 weeks after the last injection |
| Continuous subcutaneous osmotic mini-pump (ITCA 650) | Investigational; not approved |
| Oral / intranasal / inhaled | Preclinical / early formulation research |
What it does
Main effects
- Glucose-dependent insulin secretion: insulin release is enhanced only when glucose is elevated, which limits hypoglycemia risk when used alone
- Glucagon suppression: reduces inappropriately high glucagon and liver glucose output without impairing the normal glucagon response to hypoglycemia
- Slowed gastric emptying: blunts post-meal glucose spikes
- Satiety and modest weight loss: acts on hypothalamic and brainstem satiety centers; weight effects are clearly smaller than with semaglutide or tirzepatide
- Lower HbA1c and fasting and post-meal glucose in type 2 diabetes, as an adjunct to diet and exercise
- Cardiovascular safety: EXSCEL showed noninferiority to placebo for major adverse cardiovascular events (not superiority) Holman RR et al., NEJM 2017
What to watch for
Common side effects
- Nausea: the most common adverse effect, especially at initiation; also vomiting, diarrhea, reduced appetite, indigestion, constipation
- Headache, dizziness, jitteriness
- Injection-site nodules: common with the extended-release microspheres
- Hypoglycemia: mainly when combined with insulin or sulfonylureas; no increase when combined with metformin alone
- Anti-exenatide antibodies are common; high titers in a small proportion can blunt glucose control
- Serious label warnings: thyroid C-cell tumors (boxed warning for extended-release), acute pancreatitis, acute kidney injury from dehydration, drug-induced immune thrombocytopenia, anaphylaxis and angioedema, acute gallbladder disease, pulmonary aspiration during anesthesia
Key facts
Key facts worth knowing
- Exenatide was the first approved GLP-1 receptor agonist (US, 2005), backed by large RCT programs including a 14,752-patient cardiovascular outcome trial. Evidence grade A. FDA pharmacovigilance review (product history, pediatric approval)
- EXSCEL (14,752 patients, median follow-up 3.2 years): the primary outcome of cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in 11.4% on exenatide vs 12.2% on placebo (HR 0.91, 95% CI 0.83 to 1.00). Noninferior for safety, but not superior for efficacy (p = 0.06). PMID: 28910237DOI: 10.1056/NEJMoa1612917
- Exenatide-PD3 (Lancet 2025): the 194-patient, 96-week phase 3 trial found no slowing of motor progression in Parkinson's disease versus placebo (p = 0.47) and no difference on secondary measures. It is not recommended as a disease-modifying Parkinson's treatment. PMID: 39919773
- The glycine at position 2 of the 39-amino-acid sequence is what protects exenatide from DPP-4, giving it a half-life of hours rather than the minutes of native GLP-1. Byetta FDA label (structure, mechanism, description)
- All US branded exenatide products were discontinued by late October 2024 (Byetta 25 Oct 2024, Bydureon BCise 28 Oct 2024; the original Bydureon kit was withdrawn in 2021). The approval itself was not withdrawn for safety reasons. US discontinuation notice, UnitedHealthcare provider news, 2024
- Extended-release exenatide carries a boxed warning for thyroid C-cell tumors, based on tumors in rats at clinically relevant exposures. Human relevance is unknown; no clear human signal has emerged across the GLP-1 class so far. Bydureon BCise FDA label, 2025 (boxed warning, warnings list)
Legal status
Legal status
FDA-approved prescription drug (immediate-release 2005; extended-release later, with a 2021 label expansion to ages 10 and up). All US branded products are discontinued as of October 2024, so no pharmaceutical exenatide is currently marketed in the US. Availability outside the US varies by market. Not a controlled substance. Brands: Byetta, Bydureon, Bydureon BCise (aliases only).